Could the future of natural desiccated thyroid medications—and patient access to them—hang in the balance of FDA regulation?
In this episode of the Modern Thyroid and Wellness Podcast, host McCall McPherson sits down with Jeff Moshal, CEO of Genus Lifesciences Inc., for an in-depth discussion about the critical state of natural desiccated thyroid (NDT) medications, including their flagship product Ren Thyroid. Together, they break down the regulatory hurdles posed by the FDA, the history and safety of NDT, and the manufacturing processes that ensure consistency and quality.
Whether you're a patient who relies on NDT, a clinician prescribing it, or simply curious about the future of thyroid care, this episode is packed with insights, advocacy, and hope.
Jeff Moshal is the CEO of Genus Lifesciences Inc., a pharmaceutical company at the forefront of producing high-quality natural desiccated thyroid medication. Under his leadership, Genus has prioritized patient access, safety, and manufacturing integrity while actively working with advocacy groups to meet FDA approval standards.